SCNI — Scinai Immunotherapeutics Ltd.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1611747 ·
Last close
$1.55
Market Cap
$1.05M
52W High
$16.30
52W Low
$1.43
ADV30
2,273,470
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 460,000 | -1,252,000 | -2,146,000 | -2,003,000 | 17,175,000 | 2,654,000 | 5,443,000 |
| Mar 2026 | 489,000 | -1,118,000 | -2,467,000 | 3,577,000 | 17,588,000 | 2,963,000 | 5,827,000 |
| Dec 2025 | — | — | — | — | 11,626,000 | 1,661,000 | 3,523,000 |
| Jun 2025 | — | — | — | — | 11,840,000 | 989,000 | 3,982,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-5,107,000
Investing CF
$2,736,000
Financing CF
$3,592,000
CapEx
$-15,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.14
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-122,269,000
Inventory
—
Receivables
$500,000
ST Investments
—
EBIT TTM
$-8,396,000
Pretax Income TTM
$-2,760,000
Interest Exp TTM
$37,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,487,000
EBITDA
$-6,636,000
Free Cash Flow
$-3,657,250
Enterprise Value
$7,499,236
Total Cash
$2,654,000
Total Debt
$3,580,000
Shares Out
677,581
Trailing EPS
$28.07
Book Value
$10.71
ROE
-26.5%
ROA
-36.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,311,000 | -7,542,000 | -8,307,000 | 11,626,000 | 3,523,000 | 8,103,000 | -6,031,000 |
| Dec 2024 | 658,000 | -8,638,000 | 4,796,000 | 13,448,000 | 3,471,000 | 9,977,000 | -6,335,000 |
| Dec 2023 | 0 | -9,706,000 | -6,500,000 | 17,472,000 | 22,041,000 | -4,569,000 | -9,382,000 |
| Dec 2022 | 0 | -11,061,000 | -5,796,000 | 27,067,000 | 28,827,000 | -1,760,000 | -7,265,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AGTX | Agentix Corp. | $801.3K | $0.02 | — |
| CERO | CERO THERAPEUTICS HOLDINGS, INC. | $787.9K | $0.01 | — |
| SLXN | Silexion Therapeutics Corp | $1.45M | $0.26 | — |
| CRIS | CURIS INC | $2.01M | $0.83 | — |
| ABPO | Abpro Holdings, Inc. | $2.42M | $0.41 | — |
News headlines (Yahoo Finance, 1h cache)
Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement
2026-09-21 11:00 · Yahoo
Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business
2026-09-08 13:15 · Yahoo
Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum
2026-08-24 11:00 · Yahoo
Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration
2026-08-10 10:34 · Yahoo
Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives
2026-06-10 11:55 · Yahoo
Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility
2026-05-20 11:00 · Yahoo
Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe
2026-05-15 11:30 · Yahoo
Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing
2026-04-24 12:00 · Yahoo
Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration
2026-04-01 11:00 · Yahoo
Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026
2026-03-19 11:50 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.